Your browser doesn't support javascript.
loading
P2X7 receptor: the regulator of glioma tumor development and survival.
Matysniak, Damian; Chumak, Vira; Nowak, Natalia; Kukla, Artur; Lehka, Lilya; Oslislok, Magdalena; Pomorski, Pawel.
Affiliation
  • Matysniak D; Laboratory of Molecular Basis of Cell Motility, Nencki Institute of Experimental Biology of Polish Academy of Sciences, 3 Pasteur Str., 02-093, Warsaw, Poland.
  • Chumak V; Laboratory of Molecular Basis of Cell Motility, Nencki Institute of Experimental Biology of Polish Academy of Sciences, 3 Pasteur Str., 02-093, Warsaw, Poland.
  • Nowak N; Regenerative Medicine Department, Medical University of Warsaw, Warsaw, Poland.
  • Kukla A; Laboratory of Imaging Tissue Structure and Function, Nencki Institute of Experimental Biology of Polish Academy of Sciences, Warsaw, Poland.
  • Lehka L; Silesian University of Technology, Gliwice, Poland.
  • Oslislok M; Institute of Cell Biology, National Academy of Sciences of Ukraine, Lviv, Ukraine.
  • Pomorski P; Department of Embryology, Faculty of Biology, University of Warsaw, Warsaw, Poland.
Purinergic Signal ; 18(1): 135-154, 2022 03.
Article in En | MEDLINE | ID: mdl-34964926
P2X7 is an ionotropic nucleotide receptor, forming the cation channel upon ATP stimulation. It can also function as a large membrane pore as well as transmit ATP-dependent signal without forming a channel at all. P2X7 activity in somatic cells is well-known, but remains poorly studied in glioma tumors. The current paper presents the comprehensive study of P2X7 activity in C6 and glioma cell line showing the wide range of effects the receptor has on glioma biology. We observed that P2X7 stimulation boosts glioma cell proliferation and increases cell viability. P2X7 activation promoted cell adhesion, mitochondria depolarization, and reactive oxygen species overproduction in C6 cells. P2X7 receptor also influenced glioma tumor growth in vivo via activation of pro-survival signaling pathways and ATP release. Treatment with Brilliant Blue G, a selective P2X7 antagonist, effectively inhibited glioma tumor development; decreased the expression of negative prognostic cancer markers pro-survival and epithelial-mesenchymal transition (EMT)-related proteins; and modulated the immune response toward glioma tumor in vivo. Finally, pathway-specific enrichment analysis of the microarray data from human patients also showed an upregulation of P2X7 receptor in gliomas from grades I to III. The presented results shed more light on the role of P2X7 receptor in the biology of this disease.
Subject(s)
Key words

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Receptors, Purinergic P2X7 / Glioma Limits: Animals / Humans Language: En Journal: Purinergic Signal Year: 2022 Document type: Article Affiliation country: Poland Country of publication: Netherlands

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Receptors, Purinergic P2X7 / Glioma Limits: Animals / Humans Language: En Journal: Purinergic Signal Year: 2022 Document type: Article Affiliation country: Poland Country of publication: Netherlands